CTNNB1 and neoplasm: Small-molecule drug FH535 prevents both Wnt and peroxisome proliferator-activated receptor (PPAR)-mediated signaling by suppressing the recruitment of beta-catenin co-activators to target gene promoters and has been shown to be active in different tumor cell lines [90].